Lundbeck reports positive results from head-to-head study of antidepressant

Lundbeck’s antidepressant vortioxetine has reportedly demonstrated advantages compared to Pfizer’s Pristiq, which is only sold in the US.

Photo: Jens Dresling

Pharmaceutical firm Lundbeck’s antidepressant vortioxetine, which is sold under brand names Trintellix and Brintellix, has demonstrated an advantage in a head-to-head study against desvenlafaxine, which Pfizer is marketing in the US as Pristiq, Lundbeck has announced in a press release.

The study investigated the efficacy of vortioxetine in patients with Major Depressive Disorder (MDD) who had a partial response to selective serotonin reuptake inhibitor (SSRI) treatment when compared to desvenlafaxine, the statement reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs